Elanco Animal Health Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.7B | $4.4B | $4.4B | $4.4B | $4.8B |
| Cost of revenue | $2.1B | $2.0B | $1.9B | $1.9B | $2.1B |
| Gross profit | $2.6B | $2.4B | $2.5B | — | — |
| Selling, general & administrative | $1.4B | $1.3B | $1.3B | $1.3B | $1.4B |
| Research and development | $368.0M | $344.0M | $327.0M | $321.0M | $369.0M |
| Interest expense | — | — | $277.0M | $241.0M | $236.0M |
| Pretax income | -$224.0M | $488.0M | -$1.2B | -$72.0M | -$571.0M |
| Income tax expense | $8.0M | $150.0M | $36.0M | $6.0M | -$88.0M |
| Net income | -$232.0M | $338.0M | -$1.2B | -$78.0M | -$483.0M |
| Balance Sheet | |||||
| Cash and equivalents | $545.0M | $468.0M | $352.0M | $345.0M | $638.0M |
| Current assets | $3.5B | $3.2B | $3.4B | $3.3B | $3.3B |
| Total assets | $13.4B | $12.6B | $14.4B | $15.5B | $16.5B |
| Current liabilities | $1.6B | $1.3B | $1.2B | $1.7B | $1.6B |
| Total liabilities | $6.8B | $6.5B | $8.1B | $8.2B | $9.0B |
| Total debt | $3.8B | $4.3B | $5.8B | $5.9B | $6.4B |
| Stockholders' equity | $6.5B | $6.1B | $6.2B | $7.3B | $7.5B |
| Cash Flow Statement | |||||
| Cash from operations | $560.0M | $541.0M | $271.0M | $452.0M | $483.0M |
| Depreciation and amortization | $680.0M | $662.0M | $694.0M | $682.0M | $716.0M |
| Stock-based compensation | $68.0M | $55.0M | $46.0M | $59.0M | $66.0M |
| Capital expenditure | $276.0M | $147.0M | $140.0M | $171.0M | $159.0M |
| Free cash flow | $284.0M | $394.0M | $131.0M | $281.0M | $324.0M |
| Impairments | $71.0M | $81.0M | $32.0M | $0 | $66.0M |
Shares outstanding 499.4M · Free float 17.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.